Receptos Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 7:11AM CDT
- Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 -
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Receptos to Hold First Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed May 07, 9:13AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the first quarter ended March 31, 2014 on Monday, May 12 before the markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
Receptos to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Tue May 06, 9:16AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that management will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference at the Encore Hotel in Las Vegas. The presentation is scheduled for Tuesday, May 13, 2014, at 2:20 pm Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
Receptos to Present at Deutsche Bank Securities Annual Healthcare Conference
GlobeNewswire - Thu May 01, 7:13AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that its Chief Financial Officer, Graham Cooper, will be presenting at the Deutsche Bank Securities Annual Healthcare Conference at the InterContinental Hotel in Boston. The presentation is scheduled for Thursday, May 8 2014, at 11:20 am Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
GlobeNewswire - Mon Apr 28, 4:27AM CDT
Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations regarding its lead program, RPC1063, at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA. RPC1063 is the Company's sphingosine 1-phosphate 1 receptor (S1P1R) modulator in Phase 3 development for relapsing multiple sclerosis (RMS) and Phase 2 development for inflammatory bowel disease (IBD).
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
GlobeNewswire - Mon Apr 14, 3:57PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee.
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Is Teva Pharmaceutical Industries Ltd Turning a Corner?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 27, 5:30PM CDT
Once a darling of the health care space (and a frequent member of "buy and hold forever" lists), Teva Pharmaceuticals spent about three and a half years in the market's doghouse. Investors bailed out due to worries about competition in the...
3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...
Receptos to Present at BioCentury Future Leaders Conference
GlobeNewswire - Thu Mar 20, 7:14AM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that its President and Chief Executive Officer, Faheem Hasnain, will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 10:00 am Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
BioMed Realty Trust Leases Space To Life Science Firms
at Investor's Business Daily - Wed Mar 19, 4:05PM CDT
Strength in biotech stocks has been well -documented in recent months. Innovation abounds in the sector, and new companies are sprouting up all the time. BioMed Realty Trust (BMR) is a real-estate investment trust poised to benefit from continued...
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Receptos Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results
GlobeNewswire - Wed Mar 05, 3:06PM CST
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -
Receptos to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Feb 27, 8:52AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the fourth quarter and year ended December 31, 2013 on Wednesday, March 5, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Sheila Gujrathi, M.D., Joins Ambrx Board of Directors
PR Newswire - Mon Feb 24, 8:00AM CST
Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Will Receptos (RCPT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 6:25AM CST
Will Receptos (RCPT) Continue to Surge Higher?